Group 1 - The core point of the article is that Kexuan Power Holdings (00476.HK) has completed a placement of 20 million shares at a price of HKD 0.78 per share, with net proceeds of approximately HKD 15.4 million [1] - The placement was made to no less than six subscribers, and all conditions precedent of the placement agreement have been fulfilled [1] - The company plans to use the net proceeds for general working capital, with approximately HKD 12 million allocated for the development and expansion of its new energy business, particularly in electric commercial solutions [1][1] Group 2 - An additional HKD 3.4 million from the net proceeds will be used to supplement the company's general working capital [1]

配售价142.00港元较前一交易日收市价折让约[此处需补充前一交易日收市价数据才能计算折让比例]， 较前五个交易日平均收市价折让约[此处需补充前五个交易日平均收市价数据才能计算折让比例]。配售 股份占现有已发行股本约0.65%，完成后占扩大股本约0.65%。 重塑能源是一家能源集团公司，主营业务未详细提及。所得款项中，约3915万港元将用于通过偿还未偿 还银行贷款及租赁负债优化财务结构，约3915万港元用于一般公司用途。本次发行根据股东大会授予的 一般授权实施，已于2025年10月8日完成交割。 来源：新浪港股-好仓工作室 2025年10月8日，重塑能源（股份代号：2570）公告称，通过一般授权以配售新H股方式融资，发行 563,340股（约0.0亿股），募集约8000万港元（扣除费用后净得约7830万港元）。本次融资由中金公 司、招商证券国际担任联席整体协调人兼联席配售代理。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方 ...

Core Viewpoint - The Hong Kong stock market's innovative pharmaceutical sector has shown a significant rebound this year, with a notable increase in refinancing activities, reflecting the ambition of domestic innovative drug companies to expand globally and leverage differentiated innovation advantages [1] Group 1: Financing Activities - The total refinancing amount in the Hong Kong market reached HKD 173.8 billion in the first half of the year, a year-on-year increase of 227%, surpassing the total for the entire year of 2024 [1] - More than 10 innovative pharmaceutical companies in the Hong Kong market have conducted placement financing, indicating a strong demand for capital to support research and development [1] - The company Xiansheng Pharmaceutical announced a placement financing plan to raise approximately HKD 1.5535 billion by issuing 121 million shares, reflecting its strategic move during a critical development phase [2][5] Group 2: Pricing and Market Response - The placement price of HKD 12.95 per share represents an approximately 8.03% discount to the closing price on September 1, 2025, and a 6.67% discount to the average closing price over the previous five trading days, which is within the common discount range of 5%-10% for stock issuances in the Hong Kong market [5][6] - The issuance of 121 million new shares will account for approximately 4.66% of the expanded total issued share capital, balancing the company's financing needs with shareholder interests [6] - Following the announcement, the stock price of Xiansheng Pharmaceutical experienced short-term fluctuations, but the trading volume exceeded 180 million shares, setting a new record since its listing, indicating strong market interest [7] Group 3: Company Performance and Strategy - Xiansheng Pharmaceutical has transformed into a leading innovative drug company, with a reported revenue growth of 15.1% to HKD 3.585 billion and an adjusted net profit increase of 21.1% to HKD 651 million, driven primarily by its innovative drug business [8] - The company has launched ten innovative drugs, with revenue from these drugs reaching HKD 2.776 billion, a 26% increase, accounting for 77.4% of total revenue [8] - Approximately 90% of the funds raised from the placement will be allocated to research and development, focusing on core areas such as neurology, oncology, autoimmune diseases, and anti-infection, which will enhance the company's global pipeline and validate its Biopharma value [9]